| Next 10 |
Ad
AGRX News and Press Agile Therapeutics Inc.
News | Agile Therapeutics Inc. (OTCMKTS:AGRX)
-
2024-06-26 08:12:37 ET More on Agile Therapeutics Agile Therapeutics, Inc. (AGRX) Q4 2023 Earnings Call Transcript Financial information for Agile Therapeutics Read the full article on Seeking Alpha For further details see: Agile Therapeutics to be acquir...
-
2024-05-15 16:58:52 ET More on Agile Therapeutics Agile Therapeutics, Inc. (AGRX) Q4 2023 Earnings Call Transcript Agile Therapeutics Q4 2023 Earnings Preview Agile Therapeutics announces delisting from Nasdaq Financial information for Agile Therapeutics ...
- AGRX - Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pink: AGRX), a women's healthcare com...
-
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
-
2024-03-28 10:46:06 ET Agile Therapeutics, Inc. (AGRX) Q4 2023 Earnings Conference Call March 28, 2024 8:30 AM ET Company Participants Matt Riley - Head of Investor Relations and Corporate Communications Al Altomari - Chairman and Chief Executive Officer Presen...
-
2024-03-28 08:13:58 ET More on Agile Therapeutics Agile Therapeutics Q4 2023 Earnings Preview Agile Therapeutics announces delisting from Nasdaq Seeking Alpha’s Quant Rating on Agile Therapeutics Historical earnings data for Agile Therapeutics ...
-
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in First Quarter 2024 Twirla Demand Expected to Rebound in First Quarter 2...
-
Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...
-
2024-03-27 12:31:23 ET More on Agile Therapeutics Agile Therapeutics announces delisting from Nasdaq Agile Therapeutics stock soars on complete debt payoff Seeking Alpha’s Quant Rating on Agile Therapeutics Historical earnings data for Agile Therapeuti...
-
2024-03-25 16:38:08 ET More on Agile Therapeutics Agile Therapeutics stock soars on complete debt payoff Agile Therapeutics reports higher prelim FY revenue than last year Seeking Alpha’s Quant Rating on Agile Therapeutics Historical earnings data for ...
Stock Information
Get AGRX Alerts
News, Short Squeeze, Breakout and More Instantly...
Agile Therapeutics Inc. Company Name:
AGRX Stock Symbol:
OTCMKTS Market:
0.0% G/L:
$1.51 Last:
120,938 Volume:
$1.51 Open:
$1.51 Close:
Agile Therapeutics Inc. Website:
Ad
- AGRX - Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pink: AGRX), a women's healthcare com...
-
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
-
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in First Quarter 2024 Twirla Demand Expected to Rebound in First Quarter 2...